Veradigm Stock Price, News & Analysis (NASDAQ:MDRX)

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veradigm in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDRX, but not buy additional shares or sell existing shares.
View MDRX analyst ratings or view top-rated stocks.

3 equities research analysts have issued 12 month price targets for Veradigm's shares. Their MDRX share price targets range from $13.00 to $26.00. On average, they expect the company's share price to reach $18.50 in the next twelve months. This suggests a possible upside of 61.1% from the stock's current price.
View analysts price targets for MDRX or view top-rated stocks among Wall Street analysts.

Veradigm's stock was trading at $17.64 at the beginning of 2023. Since then, MDRX stock has decreased by 34.9% and is now trading at $11.48.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 30th 2023.
View our MDRX earnings forecast.

Veradigm Inc. (NASDAQ:MDRX) released its quarterly earnings results on Thursday, November, 4th. The software maker reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.09. The software maker earned $369 million during the quarter, compared to analyst estimates of $376.09 million. Veradigm's revenue was down 8.2% on a year-over-year basis. During the same quarter last year, the company posted $0.15 EPS.

ETFs with the largest weight of Veradigm (NASDAQ:MDRX) stock in their portfolio include Invesco Dynamic Software ETF (PSJ), Global X Telemedicine & Digital Health ETF (EDOC), Harbor Health Care ETF (MEDI) and Fidelity Digital Health ETF (FDHT).Invesco S&P SmallCap Health Care ETF (PSCH).

Veradigm issued an update on its FY 2023 earnings guidance on Monday, September, 18th. The company provided earnings per share (EPS) guidance of $0.80-$0.90 for the period, compared to the consensus EPS estimate of $0.87. The company issued revenue guidance of $615.00 million-$635.00 million, compared to the consensus revenue estimate of $638.08 million.

796 employees have rated Veradigm Chief Executive Officer Paul Black on Glassdoor.com. Paul Black has an approval rating of 65% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veradigm investors own include Advanced Micro Devices (AMD), Netflix (NFLX), Energy Transfer (ET), CVS Health (CVS), Ford Motor (F), Himax Technologies (HIMX), Intel (INTC), OPKO Health (OPK), Tesla (TSLA) and Activision Blizzard (ATVI).

Veradigm's stock is owned by many different retail and institutional investors. Top institutional shareholders include William Blair Investment Management LLC (4.00%), Fuller & Thaler Asset Management Inc. (2.33%), Westfield Capital Management Co. LP (2.20%), Charles Schwab Investment Management Inc. (1.75%), Northern Trust Corp (1.52%) and Jacobs Levy Equity Management Inc. (1.31%). Insiders that own company stock include David B Stevens, Elaina Shekhter, Elizabeth Ann Altman, Greg Garrison, Leah Jones, Lisa Khorey, Michael Klayko, Paul Black, Richard J Poulton, Tejal Vakharia and Thomas Langan.
View institutional ownership trends.

Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.